Genetron Holdings (NASDAQ:GTH) reported quarterly losses of $(0.37) per share. This is a 184.62 percent decrease over losses of $(0.13) per share from the same period last year.
Cantor Fitzgerald Initiates Coverage On Mereo BioPharma Group with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Overweight rating and announces Price Target of $4.